

Title: Feasibility and effects of home-based smartphone-delivered automated feedback training for gait in people with Parkinson's disease: A pilot randomized controlled trial

Authors:

Pieter Ginis ^a; Alice Nieuwboer ^{a*}; Moran Dorfman ^b; Alberto Ferrari ^c; Eran Gazit ^b; Colleen G. Canning ^d; Laura Rocchi ^c; Lorenzo Chiari ^c; Jeffrey M. Hausdorff ^{b,e,f}; Anat Mirelman ^{b,e}

Affiliations:

^a KU Leuven, Department of Rehabilitation Sciences, Neuromotor Rehabilitation Research Group, Leuven, Belgium

^b Tel Aviv Sourasky Medical Center, Department of Neurology, Center for the study of Movement, Cognition, and Mobility, Tel Aviv, Israel

^c University of Bologna, Department of Electrical, Electronic and Information Engineering – Guglielmo Marconi, Bologna, Italy

^d University of Sydney, Faculty of Health Sciences, Clinical and Rehabilitation Sciences Research Group, Sydney, Australia

^e Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

^f Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel

*** Corresponding author:**

Prof. Dr. Alice Nieuwboer

Tervuursevest 101 box 1501

3001 Leuven

BELGIUM

Tel.: +32 (0)16 329119

E-mail: alice.nieuwboer@faber.kuleuven.be

1 **E-mail addresses:**

2 P. Ginis: pieter.ginis@faber.kuleuven.be

3 A. Nieuwboer: alice.nieuwboer@faber.kuleuven.be

4 M. Dorfman: morando@tlvmc.gov.il

5 A. Ferrari: alberto.ferrari@unibo.it

6 E. Gazit: erang@tlvmc.gov.il

7 C. Canning: colleen.canning@sydney.edu.au

8 L. Rocchi: l.rocchi@unibo.it

9 L. Chiari: lorenzo.chiari@unibo.it

10 J.M. Hausdorff: jhausdor@tlvmc.gov.il

11 A. Mirelman: anatmi@tlvmc.gov.il

12

Keywords: Parkinson's disease; physical therapy; gait training; auditory feedback; wearable sensor

Abstract

Background

Inertial measurement units combined with a smartphone application (CuPiD-system) were developed to provide people with Parkinson's disease (PD) real-time feedback on gait performance. This study investigated the CuPiD-system's feasibility and effectiveness compared with conventional gait training when applied in the home environment.

Methods

Forty persons with PD undertook gait training for 30 minutes, three times per week for six weeks. Participants were randomly assigned to i) CuPiD, in which a smartphone application offered positive and corrective feedback on gait, or ii) an active control, in which personalized gait advice was provided. Gait, balance, endurance and quality of life were assessed before and after training and at four weeks follow-up using standardized tests.

Results

Both groups improved significantly on the primary outcomes (single and dual task gait speed) at post-test and follow-up. The CuPiD group improved significantly more on balance (MiniBESTest) at post-test (from 24.8 to 26.1, SD~5) and maintained quality of life (SF-36 physical health) at follow-up whereas the control group deteriorated (from 50.4 to 48.3, SD~16). No other statistically significant differences were found between the two groups. The CuPiD system was well-tolerated and participants found the tool user-friendly.

Conclusion

1 CuPiD was feasible, well-accepted and seemed to be an effective approach to promote gait training,
2 as participants improved equally to controls. This benefit may be ascribed to the real-time feedback,
3 stimulating corrective actions and promoting self-efficacy to achieve optimal performance. Further
4 optimization of the system and adequately-powered studies are warranted to corroborate these
5 findings and determine cost-effectiveness.

6

1 **Introduction**

2 In Parkinson's disease (PD), gait and balance deficits, and more specifically freezing of gait
3 (FOG), result in reduced quality of life [1]. Exercise has been shown to improve PD motor
4 impairments in the short term [2, 3]. Also, it has been suggested that exercise effects can be
5 enhanced by increasing subjects' cognitive engagement with practice through the provision of cueing
6 or biofeedback in PD [4, 5]. Cueing is defined as temporal or spatial stimuli, which regulate and
7 facilitate repetitive movements by providing an explicit motor target. Several systematic reviews
8 indicate that different cueing modalities have an immediate effect on gait and health related quality
9 of life (HR-QoL) [6-8], and increase retention of learning in PD [9, 10]. In addition, cueing reduces the
10 severity of Freezing of Gait (FOG) [9, 11, 12]. Biofeedback refers to the provision of external
11 information during or immediately after movement, which supplements sensory (proprioceptive)
12 pathways to guide motor performance. Although augmented feedback has been shown to be
13 effective for improving balance [13-15] and gait [16], it usually requires cumbersome laboratory
14 setups and specialized healthcare professionals to administer. Combined with the increasing
15 prevalence of PD and the predicted shortage of physiotherapists [17], new ways to deliver cueing
16 and biofeedback seem therefore warranted.

17 Current wearable technology in PD is mainly directed towards long-term, home assessment
18 of disease symptoms [18], rather than therapy [19]. To our knowledge, only Espay et al. investigated
19 at-home training with wearable biofeedback technology and showed it was effective to improve gait
20 in PD, although a control group was lacking [20]. In addition, FOG can now be detected reliably in
21 real-time using inertial measurement units (IMUs) in a standardized setting, but home detection has
22 not been investigated yet [21, 22]. A six week training period using a FOG specific instrumented
23 cueing method in the laboratory, found a reduction of FOG episodes but no carry-over to daily life
24 [23]. These results highlight the challenge of designing appropriate technology, which aims to
25 address the needs of people with PD in the home environment [19].

1 The current study is part of the EU-funded CuPiD-project (www.cupid-project.eu).
2 Innovatively, and in line with recent evolutions [24, 25], we designed a gait training application not
3 only with a team of engineers and physiotherapists, but also with the active participation of persons
4 with PD. The technology integrates 3 main functions: 1) measurement of gait in real-time; 2) auditory
5 biofeedback (ABF) on one or more spatiotemporal gait parameters [26]; and 3) rhythmical auditory
6 cueing to prevent or overcome FOG episodes [22]. The aims of the present study were to test the
7 feasibility of training with the CuPiD system in the home environment, and to discover the
8 differential effects of CuPiD training versus conventional home-based gait intervention on gait,
9 balance and HR-QoL in PD. We hypothesized that both interventions would improve gait and balance
10 outcomes, as participants would be stimulated to increase walking, but that the effects would be
11 amplified in the CuPiD group because of the cognitive engagement by the wearable biofeedback.

13 **Methods**

14 *Participants*

15 Forty PD persons were recruited by telephone from databases of the Department of
16 Rehabilitation Sciences, KU Leuven (Belgium) and the Tel Aviv Sourasky Medical Center (Israel)
17 (Figure 1). Participants were included if they were able to walk for 10 minutes continuously; had a
18 score of 24 or higher on the Montreal Cognitive Assessment (MoCA); were in Hoehn & Yahr Stage II
19 to III in ON-state and were on stable PD medication. People were excluded if they had severe medical
20 conditions affecting gait other than PD, had hearing or visual problems precluding benefiting from
21 auditory feedback and were likely to change medication regimen during the course of the study.
22 Participants were allowed to continue with their usual care including their regular physiotherapy.
23 After baseline screening, participants were randomly allocated to the CuPiD or control group per
24 center by the researcher, who was not blind to group allocation. A stratified blocked randomization
25 procedure was used (Hoehn & Yahr stage, having FOG or not). The study was approved by the local

ethics committee of the University Hospitals Leuven and Tel Aviv Sourasky Medical Center. All participants gave written consent according to the declaration of Helsinki.

CuPiD system

The CuPiD system consisted of a smartphone (Galaxy S3-mini, Samsung, South Korea), a docking station and two IMUs (EXLs3, EXEL srl., Italy) with a sampling frequency of 100Hz (Figure 2A in supplementary materials). Technical features and algorithms were first validated for the detection of gait abnormalities against standard gait registration systems [26], and for FOG detection in a laboratory environment [22]. Ten people with PD (5 from each country) extensively tested the system prior to trial commencement. Battery life ensured a user-duration of up to 4 hours.

Two applications were used in this study: the audio-biofeedback (ABF-gait app) and the instrumented cueing for FOG-training (FOG-cue app). Feedback and cues were provided via earphones or the smartphone's speaker. The ABF-gait app contained:

- 1) A large touch-screen "Start" button, establishing the connection with the IMUs (see figure 2A);
- 2) A menu of four training targets: cadence, stride length, symmetry and gait speed;
- 3) A 'therapeutic window' allowing calibration of feedback according to the individual's optimal gait performance [26], and set per gait parameter as a percentage above and below the median of every 5 steps (see figure 2B). Positive verbal feedback (in Dutch or Hebrew) was given when gait remained within the therapeutic window, diminishing with an exponential trend to prevent feedback overload and maximize motor learning. Corrective verbal feedback was given when gait parameters fell outside the therapeutic window. Figure 3 shows training examples of 2 PD persons (see supplementary materials).

The FOG-cue app contained:

- 1) A FOG detection sensitivity option, adjusted by the physiotherapist to low or high to accommodate excessive false positive or false negative detections.

2) An exercise menu, including walking in a figure of 8, maneuvering through cluttered spaces and making turns with and without responding to a visual GO-NO-GO signal provided by the smartphone.

3) Intelligent cueing options, providing continuous cueing during walking which faded when FOG occurred or was initiated when FOG was detected (based on the person's preference).

Intervention

A. CuPiD training

CuPiD group participants received weekly home visits from the researcher during the six week of intervention. Participants were instructed to walk at least 3 times per week for 30 minutes, according to ACSM's exercise guidelines for health benefits [27]. They were instructed to use the ABF-gait app, which provided feedback on selected gait parameters during their walks. Participants with FOG received instruction on how to avoid FOG and practiced for an additional 30 minutes three times a week using the FOG-cue app, similar to previous work [23].

The smartphone was carried in a pocket of the participant's clothing, except for during FOG-training when the phone was handheld (to see the visual signals). Participants were taught how to apply the IMUs to their shoes (when using the ABF-gait app) and above their ankles when using the FOG-cue app. A booklet with pictures and personalized instructions was left in the home and consultation by telephone was offered in case of difficulties using the system. An optimal performance walk was performed during the initial visit and repeated twice over the 6-week study period to calibrate the ABF-gait app. Spatiotemporal parameters and FOG-cue settings were on average 4 times adjusted by the researcher during weekly visits.

Participants were asked to record the frequency and duration of their training sessions in a diary. The CuPiD system also recorded the duration of walks with the system. Training data were provided in summary statistics, consisting of simple displays of positive and corrective feedback received and number of steps performed.

Control training

The control group also received weekly visits by the same researcher for six weeks and was provided with the same practice schedule, personalized approach and recommendations for training, except for the CUPID system. Control participants also recorded the frequency and duration of their training sessions in a diary. People allocated to this group were informed about the documented effectiveness of the intervention.

Assessment procedure and outcomes

During the first session (pre-test), in- and exclusion criteria were checked and baseline values of the primary and secondary outcomes collected. The same outcomes were assessed after the 6 weeks intervention (post-test) and after a 4 week (follow-up) period by the same assessor at each clinical center. Testers were not blinded to group allocation. Measurements' order was standardized within the test procedure and conducted when participants were optimally medicated, about 1 hour after PD medication intake.

Primary outcomes were gait speed under usual and dual task conditions. We were particularly interested in detecting changes in DT gait speed, as it may better represent improved gait automaticity than single task outcomes. Participants were asked to walk for one minute over an instrumented walkway (PKMAS, Protokinetics, USA): (1) at comfortable speed and (2) while reciting as many words as possible starting with a pre-specified letter. Secondary gait, balance and HR-QoL outcomes included the 2 Minute Walk Test (2MWT) [28], the mini-Balance Evaluation Systems Test (MiniBESTest) [29], the Four Square Step Test (FSST) [30], the Falls Efficacy Scale-International (FES-I) [31] and the Physical Activity Scale for the Elderly (PASE) [32]. FOG severity was determined by the New-FOG questionnaire (NFOG-Q) [33] and the Ziegler protocol [34]. Disease severity was quantified using the Movement Disorders Unified Parkinson's Disease Rating Scale – motor examination (UPDRS III) [35]. Cognitive assessments included Color Trail Test (CTT) A and B [36] and verbal fluency (VF) scores in sitting and walking. Quality of life was determined by the Short Form 36 Health Survey (SF-

36) [37]. At post-test, a 5-item Likert scale investigated whether participants found the CuPiD system user-friendly or not (1 = no agreement and 5 = total agreement).

Statistical analysis

Kolmogorov-Smirnov analysis and Levene's test evaluated the data distribution. In case of abnormal distributions, non-parametric analyses were performed. As this did not lead to different results, only parametric test results are reported.

To compare baseline characteristics and adherence outcomes between both groups, an independent samples T-test was used for continuous and a chi-square for categorical variables. A 2 (group) by 3 (time: pre-test/post-test/follow-up) repeated measures ANOVA evaluated differences for the dependent variables on the primary and secondary outcomes, being the independent variables. Because of the exploratory nature of this trial, Fisher's LSD post-hoc analyses were applied. Effect sizes expressed as partial eta squared (η^2) are reported for the most important findings. The level of statistical significance was set at $\alpha = 0.05$.

We report the data from all participants who completed the 6 weeks of training (per protocol analysis) and also conducted an intention-to-treat analysis with a last observation carried forward method to impute missing values. Statistical analysis was performed using SPSS version 22 (IBM, USA).

Results

Twenty-two participants were allocated to CuPiD, of which 20 completed training. Eighteen participants were allocated to the control arm, all of whom completed training (Figure 1). Reasons for dropout (N=2) were unrelated to CuPiD in one person. However, the second person was unable to cope with the CuPiD system without supervision at home. Both training groups were similar at baseline (see supplementary materials: table S1). Fourteen CuPiD participants and 10 control

participants experienced FOG. Only 11 participants (29%) had used a smartphone before entering the study.

Gait

There were no interaction effects for the primary outcomes (table 1), gait speed under single tasking ($F_{(2,108)}=1.11$, $p=0.34$, $\eta^2 = 0.03$) and gait speed under dual tasking ($F_{(2,108)}=1.14$, $p=0.33$, $\eta^2 = 0.03$). Also the group differences for the primary outcomes, were not significantly different (Single tasking: $F_{(1,108)}=0.15$, $p=0.70$, $\eta^2 = 0.01$; Dual tasking: $F_{(1,108)}=0.19$, $p=0.66$, $\eta^2 = 0.01$). However, there was a main effect of time (Single tasking: $F_{(2,108)}=14.31$, $p<0.001$, $\eta^2 = 0.29$; Dual tasking: $F_{(2,108)}=9.57$, $p<0.001$, $\eta^2 = 0.23$). These results indicate that both groups improved gait speed during single and dual tasking from pre-test to post-test, whereby the CuPiD group improved their gait speed with 9.0% and 13.5% and the control group with 5.2% and 5.8% for single and dual tasking, respectively. Other gait outcomes showed a similar pattern of results and most gait benefits were maintained at follow-up in both groups.

Balance

A significant time by group interaction was found for the miniBESTest ($F_{(2,108)}=3.73$, $p=0.04$, $\eta^2 = 0.11$), indicating that the improvement in balance for the CuPiD group was significantly greater than the control group at post-test (table 1). However, this effect was not maintained at follow-up. This result was also reflected with a trend towards a significant interaction effect of time by group for the FSST ($F_{(2,108)}=3.38$, $p=0.09$, $\eta^2 = 0.10$).

Endurance

The aforementioned gait improvements were also reflected in the 2MWT which showed a significant main effect of time ($F_{(2,108)}=4.32$, $p<0.005$, $\eta^2 = 0.11$) as shown in table 1.

Health related quality of life

A significant time by group interaction was found for the physical health score of the SF-36 ($F_{(2,108)}=1.85$, $p<0.05$, $\eta^2 = 0.06$), indicating that the control group experienced a decrease in self-reported physical health at follow-up, while the CuPiD group did not.

There were no significant between-group or within-group differences for FOG outcomes and cognitive measures. Intention-to-treat analysis yielded similar results with the exception that the time by group interactions for the MiniBESTest and SF-36 (physical health) were no longer significant (both $p=0.07$).

Feasibility

Adherence data (Table 2) showed that the CuPiD group spent less time training compared to the control group, while the number of training sessions was identical (CuPiD: 28 ± 9 sessions; control: 28 ± 10 sessions; $p=0.91$). Training duration was based on the CuPiD system logs for the CuPiD group, and diary data for the control group. When checking for differences between diaries and CuPiD logs in 13 CuPiD participants, diary notations (701 ± 304 min.) were not significantly different from CuPiD logs (646 ± 254 min.; $p=0.25$). Participants with incomplete diary data, were excluded from this analysis.

In general, participants were very positive about the CuPiD system, as scores on user-friendliness were on average above 4 on a 5-point scale. However, attaching and removing the IMUs and using the CuPiD system without technical support resulted in more variable answers (Table 1). It was observed that participants with previous smartphone experience had the least problems using the CuPiD system. Some participants were so enthusiastic about the system that they expressed disappointment after its withdrawal.

Discussion

1 This phase II RCT investigated the feasibility of the CuPiD system and its effectiveness on gait
2 and balance, compared to conventional gait training in people with PD. The system was well-
3 accepted and showed to be useful for providing minimally supervised at-home gait training. Both
4 study arms improved on the primary outcomes of gait speed under comfortable and dual task
5 conditions at post-test and at follow-up. The CuPiD approach demonstrated to be better at
6 improving balance than conventional gait training in people with PD.

7 Despite the non-superior findings of the CuPiD system for gait, the results revealed a larger
8 improvement in gait speed during both comfortable (9.0%) and dual task conditions (13.5%),
9 whereas controls improved gait speed by only 5.2% and 5.8%. According to the recommendations by
10 Hass et al., the control group's effect sizes can be interpreted as small [38], whereas those of the
11 CuPiD group can be considered as clinically moderate and as comparable to other cueing and
12 treadmill studies [9, 16, 39]. These results are the more notable, considering that total training time
13 was lower in the CuPiD group, suggesting that the CuPiD system may have improved training
14 efficiency.

15 In contrast to gait, we found an interaction effect for the MiniBESTest balance outcome
16 favoring the CuPiD group. However, it should be noted that the between-group mean difference for
17 the MiniBESTest of 1.7 points is below the smallest real difference of 3.4 points [40]. CuPiD
18 participants also tended to improve more than controls on the FSST, another test of dynamic
19 stability, requiring fast steps in different directions over a small obstacle. Together, these findings
20 suggest that CuPiD induced benefits of dynamic stability, which may be ascribed to the fact that
21 CuPiD targeted larger step sizes and greater gait stability.

22 There were no between- or within-group effects on FOG, although pre- to post-test
23 differences of 1.5 points in NFOG-Q scores were found in favor of the CuPiD group. Since both groups
24 devoted less time to training FOG, it is possible that the dose was insufficient to be effective. In
25 addition, FOG training was only undertaken by 17 participants. Therefore, the study was not
26 powered to detect significant differences.

1 This study showed that the CuPiD group trained as much as the control group in terms of
2 training sessions, but had a lower training duration. Possible explanations could be related to the
3 self-reporting of adherence, overestimating actual compliance for reasons of social desirability.
4 However, when training diaries and CuPiD logs were compared, no significant differences were
5 detected, albeit in participants with complete diaries only. The fact that CuPiD participants were
6 aware that their training was logged, may also have contributed to this finding. The number of
7 training sessions was similar in both groups, indicating that the intention to train was equal in both
8 groups. Also, the reported training duration is in line with earlier reported adherence of
9 approximately 80% in home-based PD interventions [41, 42]. The CuPiD system was used with
10 minimal supervision, while most participants were unfamiliar with a smartphone. Except for
11 difficulties with the correct placement of the IMUs and the touchscreen the system was very well-
12 tolerated as indicated by the positive scores on the user-friendliness scale.

13 Lack of statistical confirmation of the CuPiD system's benefits may indicate that it does not
14 offer an added clinical value. Alternatively, the study may have been underpowered to show a
15 surplus effect. Post-hoc power calculations based on the dual task gait speed results showed that 164
16 (82 per group) persons would be required to achieve the desired power of 0.80 assuming effect sizes
17 of 13.5% for the CuPiD group and 5.8% for controls. However, when compared against a passive
18 control group, a total of 54 (27 per group) participants would suffice. Other limitations which may
19 have influenced the trial outcomes, were the lack of assessor blinding for group allocation and
20 uncorrected post-hoc analyses for multiple comparisons. Also, the placebo effect resulting from
21 increased attention during therapy was not controlled for and we did not take usual care
22 characteristics into consideration. Despite these drawbacks, we conclude that the CuPiD system was
23 feasible for unsupervised home-use and was an effective approach for gait and balance training in
24 PD. Given the shorter training duration with the CuPiD systems, these benefits may possibly be
25 associated with the online biofeedback model, enhancing training efficiency. Large scale clinical trials

to investigate its long-term use and cost-effectiveness are indicated before future implementation can be considered.

Conflict of interest

AF and LC have a significant financial interest in mHealth Technologies, a company that may have a commercial interest in the results of this research and technology. All other authors declare no competing interests.

Funding sources

The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 288516 (CuPiD project).

Authors' contribution

All authors contributed to the research design. PG, MD and EG were responsible for recruitment, home-based training and assessments. PG was principally responsible for data-analysis and drafting of the manuscript. AF was responsible for implementing necessary adjustments to the CuPiD system. All authors critically reviewed the manuscript and approved the submitted version.

Acknowledgments

The authors would like to thank all volunteers who were willing to participate in this study.

1 **References**

- 2 [1] D. Muslimovic, B. Post, J.D. Speelman, B. Schmand, R.J. de Haan, Determinants of disability and
3 quality of life in mild to moderate Parkinson disease, *Neurology*. 70 (2008) 2241-2247.
- 4 [2] V.A. Goodwin, S.H. Richards, R.S. Taylor, A.H. Taylor, J.L. Campbell, The effectiveness of
5 exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis,
6 *Mov Disord*. 23 (2008) 631-640.
- 7 [3] C.L. Tomlinson, S. Patel, C. Meek, C.P. Herd, C.E. Clarke, R. Stowe, et al., Physiotherapy
8 intervention in Parkinson's disease: systematic review and meta-analysis, *Bmj*. 345 (2012) e5004.
- 9 [4] G.M. Petzinger, B.E. Fisher, S. McEwen, J.A. Beeler, J.P. Walsh, M.W. Jakowec, Exercise-
10 enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease, *Lancet Neurol*.
11 12 (2013) 716-726.
- 12 [5] E.E.H. van Wegen, M.A. Hirsch, M. Huiskamp, G. Kwakkel, Harnessing Cueing Training for
13 Neuroplasticity in Parkinson Disease, *Top Geriatr Rehabil*. 30 (2014) 46-57.
- 14 [6] I. Lim, E. van Wegen, C. de Goede, M. Deutekom, A. Nieuwboer, A. Willems, et al., Effects of
15 external rhythmical cueing on gait in patients with Parkinson's disease: a systematic review, *Clin*
16 *Rehabil*. 19 (2005) 695-713.
- 17 [7] S.J. Spaulding, B. Barber, M. Colby, B. Cormack, T. Mick, M.E. Jenkins, Cueing and gait
18 improvement among people with Parkinson's disease: a meta-analysis, *Arch Phys Med Rehabil*. 94
19 (2013) 562-570.
- 20 [8] P.A. Rocha, G.M. Porfirio, H.B. Ferraz, V.F. Trevisani, Effects of external cues on gait parameters
21 of Parkinson's disease patients: a systematic review, *Clin Neurol Neurosurg*. 124 (2014) 127-134.
- 22 [9] A. Nieuwboer, G. Kwakkel, L. Rochester, D. Jones, E. van Wegen, A.M. Willems, et al., Cueing
23 training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial, *J Neurol*
24 *Neurosurg Psychiatry*. 78 (2007) 134-140.
- 25 [10] L. Rochester, K. Baker, V. Hetherington, D. Jones, A.M. Willems, G. Kwakkel, et al., Evidence for
26 motor learning in Parkinson's disease: acquisition, automaticity and retention of cued gait performance
27 after training with external rhythmical cues, *Brain Res*. 1319 (2010) 103-111.
- 28 [11] G. Frazzitta, R. Maestri, D. Uccellini, G. Bertotti, P. Abelli, Rehabilitation treatment of gait in
29 patients with Parkinson's disease with freezing: a comparison between two physical therapy protocols
30 using visual and auditory cues with or without treadmill training, *Mov Disord*. 24 (2009) 1139-1143.

- [12] U.M. Fietzek, F.E. Schroeteler, K. Ziegler, J. Zwosta, A.O. Ceballos-Baumann, Randomized cross-over trial to investigate the efficacy of a two-week physiotherapy programme with repetitive exercises of cueing to reduce the severity of freezing of gait in patients with Parkinson's disease, *Clin Rehabil.* 28 (2014) 902-911.
- [13] A. Mirelman, T. Herman, S. Nicolai, A. Zijlstra, W. Zijlstra, C. Becker, et al., Audio-biofeedback training for posture and balance in patients with Parkinson's disease, *J Neuroeng Rehabil.* 8 (2011) 35.
- [14] M.R. van den Heuvel, G. Kwakkel, P.J. Beek, H.W. Berendse, A. Daffertshofer, E.E. van Wegen, Effects of augmented visual feedback during balance training in Parkinson's disease: a pilot randomized clinical trial, *Parkinsonism Relat Disord.* 20 (2014) 1352-1358.
- [15] C.Y. Yen, K.H. Lin, M.H. Hu, R.M. Wu, T.W. Lu, C.H. Lin, Effects of virtual reality-augmented balance training on sensory organization and attentional demand for postural control in people with Parkinson disease: a randomized controlled trial, *Phys Ther.* 91 (2011) 862-874.
- [16] A. Mirelman, I. Maidan, T. Herman, J.E. Deutsch, N. Giladi, J.M. Hausdorff, Virtual reality for gait training: can it induce motor learning to enhance complex walking and reduce fall risk in patients with Parkinson's disease?, *J Gerontol A Biol Sci Med Sci.* 66 (2011) 234-240.
- [17] J.L. Zimbelman, S.P. Juraschek, X.M. Zhang, V.W.H. Lin, Physical Therapy Workforce in the United States: Forecasting Nationwide Shortages, *Pm&R.* 2 (2010) 1021-1029.
- [18] W. Maetzler, J. Domingos, K. Srulijes, J.J. Ferreira, B.R. Bloem, Quantitative wearable sensors for objective assessment of Parkinson's disease, *Mov Disord.* 28 (2013) 1628-1637.
- [19] P.B. Shull, W. Jirattigalachote, M.A. Hunt, M.R. Cutkosky, S.L. Delp, Quantified self and human movement: a review on the clinical impact of wearable sensing and feedback for gait analysis and intervention, *Gait Posture.* 40 (2014) 11-19.
- [20] A.J. Espay, Y. Baram, A.K. Dwivedi, R. Shukla, M. Gartner, L. Gaines, et al., At-home training with closed-loop augmented-reality cueing device for improving gait in patients with Parkinson disease, *The Journal of Rehabilitation Research and Development.* 47 (2010) 573-582.
- [21] M. Bachlin, M. Plotnik, D. Roggen, N. Giladi, J.M. Hausdorff, G. Troster, A wearable system to assist walking of Parkinson's disease patients, *Methods Inf Med.* 49 (2010) 88-95.
- [22] S. Mazilu, U. Blanke, M. Hardegger, G. Troster, E. Gazit, M. Dorfman, et al., GaitAssist: A Wearable Assistant for Gait Training and Rehabilitation in Parkinson's Disease, 2014 IEEE

International Conference on Pervasive Computing and Communications Workshops (Percom Workshops). (2014) 135-137.

[23] M. Plotnik, S. Shema, M. Dorfman, E. Gazit, M. Brozgol, N. Giladi, et al., A motor learning-based intervention to ameliorate freezing of gait in subjects with Parkinson's disease, *J Neurol*. 261 (2014) 1329-1339.

[24] K. Schipper, L. Dauwerse, A. Hendriks, J.W. Leedekerken, T.A. Abma, Living with Parkinson's disease: priorities for research suggested by patients, *Parkinsonism Relat Disord*. 20 (2014) 862-866.

[25] R. Fleurence, J.V. Selby, K. Odom-Walker, G. Hunt, D. Meltzer, J.R. Slutsky, et al., How the Patient-Centered Outcomes Research Institute is engaging patients and others in shaping its research agenda, *Health Aff (Millwood)*. 32 (2013) 393-400.

[26] F. Casamassima, A. Ferrari, B. Milosevic, P. Ginis, E. Farella, L. Rocchi, A wearable system for gait training in subjects with Parkinson's disease, *Sensors (Basel)*. 14 (2014) 6229-6246.

[27] C.E. Garber, B. Blissmer, M.R. Deschenes, B.A. Franklin, M.J. Lamonte, I.M. Lee, et al., American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise, *Med Sci Sports Exerc*. 43 (2011) 1334-1359.

[28] P. Rossier, D.T. Wade, Validity and reliability comparison of 4 mobility measures in patients presenting with neurologic impairment, *Arch Phys Med Rehabil*. 82 (2001) 9-13.

[29] A.L. Leddy, B.E. Cwoner, G.M. Earhart, Utility of the Mini-BESTest, BESTest, and BESTest sections for balance assessments in individuals with Parkinson disease, *J Neurol Phys Ther*. 35 (2011) 90-97.

[30] R.P. Duncan, G.M. Earhart, Four square step test performance in people with Parkinson disease, *J Neurol Phys Ther*. 37 (2013) 2-8.

[31] K.A. Hauer, G.I. Kempen, M. Schwenk, L. Yardley, N. Beyer, C. Todd, et al., Validity and sensitivity to change of the falls efficacy scales international to assess fear of falling in older adults with and without cognitive impairment, *Gerontology*. 57 (2011) 462-472.

[32] R.A. Washburn, K.W. Smith, A.M. Jette, C.A. Janney, The Physical Activity Scale for the Elderly (PASE): development and evaluation, *J Clin Epidemiol*. 46 (1993) 153-162.

- [33] A. Nieuwboer, L. Rochester, T. Herman, W. Vandenberghe, G.E. Emil, T. Thomaes, et al., Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson's disease and their carers, *Gait Posture*. 30 (2009) 459-463.
- [34] K. Ziegler, F. Schroeteler, A.O. Ceballos-Baumann, U.M. Fietzek, A new rating instrument to assess festination and freezing gait in Parkinsonian patients, *Mov Disord*. 25 (2010) 1012-1018.
- [35] C.G. Goetz, B.C. Tilley, S.R. Shaftman, G.T. Stebbins, S. Fahn, P. Martinez-Martin, et al., Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results, *Mov Disord*. 23 (2008) 2129-2170.
- [36] I. Sanchez-Cubillo, J.A. Perianez, D. Adrover-Roig, J.M. Rodriguez-Sanchez, M. Rios-Lago, J. Tirapu, et al., Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities, *J Int Neuropsychol Soc*. 15 (2009) 438-450.
- [37] A. Riazi, J.C. Hobart, D.L. Lamping, R. Fitzpatrick, J.A. Freeman, C. Jenkinson, et al., Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles, *J Neurol Neurosurg Psychiatry*. 74 (2003) 710-714.
- [38] C.J. Hass, M. Bishop, M. Moscovich, E.L. Stegemoller, J. Skinner, I.A. Malaty, et al., Defining the clinically meaningful difference in gait speed in persons with Parkinson disease, *J Neurol Phys Ther*. 38 (2014) 233-238.
- [39] T. Herman, N. Giladi, L. Gruendlinger, J.M. Hausdorff, Six weeks of intensive treadmill training improves gait and quality of life in patients with Parkinson's disease: a pilot study, *Arch Phys Med Rehabil*. 88 (2007) 1154-1158.
- [40] N. Lofgren, E. Lenholm, D. Conradsson, A. Stahle, E. Franzen, The Mini-BESTest--a clinically reproducible tool for balance evaluations in mild to moderate Parkinson's disease?, *BMC Neurol*. 14 (2014) 235.
- [41] C.G. Canning, N.E. Allen, C.M. Dean, L. Goh, V.S. Fung, Home-based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial, *Clin Rehabil*. 26 (2012) 817-826.
- [42] T. Martin, M. Weatherall, T.J. Anderson, M.R. MacAskill, A Randomized Controlled Feasibility Trial of a Specific Cueing Program for Falls Management in Persons With Parkinson Disease and Freezing of Gait, *J Neurol Phys Ther*. 39 (2015) 179-184.

Table 1 Outcomes of PD persons who completed the training period

	CuPiD (n=20)			Control (n=18)			Effects		
Variables	Pretest	Posttest	Follow-up	Pretest	Posttest	Follow-up	Time	Group	Time x Group
Comfortable gait									
Gait speed [m/s]	1.11 (0.23)	1.21 (0.24) ^a	1.22 (0.23) ^a	1.16 (0.14)	1.22 (0.14) ^a	1.24 (0.17) ^a	P<0.001	P=0.70	P=0.34
Stride length [m]	1.18 (0.22)	1.26 (0.21) ^a	1.26 (0.21) ^a	1.26 (0.16)	1.32 (0.14) ^a	1.31 (0.17) ^a	P<0.001	P=0.31	P=0.31
DS time [% GCT]	32.42 (4.62)	30.71 (3.99) ^a	30.59 (4.28) ^a	29.51 (3.12)	28.79 (3.26) ^a	28.88 (3.59) ^a	P<0.01	P=0.07	P=0.17
Dual task gait									
Gait speed [m/s]	0.96 (0.24)	1.09 (0.28) ^a	1.07 (0.27) ^a	1.03 (0.12)	1.09 (0.11) ^a	1.09 (0.17) ^a	P<0.001	P=0.66	P=0.33
Stride length [m]	1.07 (0.22)	1.16 (0.26) ^a	1.14 (0.24) ^a	1.15 (0.14)	1.21 (0.11) ^a	1.19 (0.18) ^a	P<0.001	P=0.35	P=0.51
DS time [% GCT]	34.70 (4.81)	32.64 (4.60) ^a	32.94 (4.75)	31.78 (3.26)	31.02 (3.58) ^a	31.51 (4.05)	P<0.01	P=0.12	P=0.22
Balance									
MiniBESTest [0-32]	24.75 (5.61)	26.10 (4.64) ^a	24.95 (4.78)	25.33 (4.04)	24.44 (4.96)	25.00 (4.89)	P=0.79	P=0.82	P=0.04
FSST [s]	11.02 (3.57)	9.70 (2.28)	9.86 (3.34) ^a	10.26 (2.21)	10.51 (3.53)	10.12 (2.59) ^a	P<0.05	P=0.92	P=0.09
FES-I [16-64]	26.90 (7.21)	27.35 (9.45)	26.74 (9.57)	27.28 (10.02)	27.82 (12.07)	28.00 (9.93)	P=0.91	P=0.84	P=0.89
Endurance and physical capacity									
2 MWT [m]	145.56 (38.17)	157.54 (39.23) ^a	152.47 (43.38)	150.09 (25.89)	153.89 (25.20) ^a	154.97 (24.18)	P<0.005	P=0.95	P=0.15
PASE [0-400]	125.86 (85.56)	115.31 (73.77)	102.30 (68.55)	103.30 (60.37)	102.66 (50.00)	99.92 (48.19)	P=0.18	P=0.52	P=0.56
Disease severity									
UPDRS III [0-132]	28.35 (14.77)	28.15 (15.57)	30.85 (14.26)	33.77 (14.36)	31.00 (14.62)	34.65 (15.21)	P=0.09	P=0.44	P=0.64
Freezing of Gait ¹									
NFOG-Q [0-28]	14.43 (7.84)	12.93 (7.65)	13.93 (8.27)	13.70 (7.82)	15.10 (6.57)	15.70 (7.30)	P=0.49	P=0.73	P=0.19
Ziegler [0-36]	5.50 (8.25)	5.07 (6.97)	5.00 (6.67)	4.40 (4.12)	4.00 (6.91)	4.30 (4.27)	P=0.79	P=0.69	P=0.93
Cognition									

CTT-A [s]	73.65 (34.67)	58.70 (26.27)	64.30 (29.87)	59.78 (19.16)	69.94 (47.08)	64.77 (26.59)	P=0.08	P=0.67	P=0.08
CTT-B [s]	136.32 (59.42)	142.95 (67.38)	126.00 (60.25)	122.33 (66.07)	119.78 (56.24)	120.65 (58.93)	P=0.23	P=0.36	P=0.25
VF Sit [#]	30.05 (12.19)	29.50 (14.89)	27.75 (14.43)	31.78 (16.95)	31.22 (17.84)	32.88 (22.02)	P=0.86	P=0.58	P=0.46
VF Walk [#]	11.00 (5.06)	10.20 (4.56)	10.35 (5.58)	10.28 (6.32)	10.33 (6.82)	11.18 (7.49)	P=0.59	P=0.99	P=0.47
<i>Quality of life</i>									
SF-36 [0-100]	58.59 (18.60)	59.76 (17.95)	59.46 (17.13)	53.24 (16.55)	59.28 (18.73)	53.81 (20.42)	P=0.23	P=0.51	P=0.65
SF-36 Phys. health [0-100]	53.79 (18.50)	53.28 (18.45)	54.80 (16.48)	50.41 (15.60)	56.67 (17.32)	48.29 (15.54) ^b	P=0.21	P=0.71	P<0.05
SF-36 Ment. health [0-100]	59.76 (18.01)	63.56 (18.41)	60.60 (18.05)	55.00 (18.69)	58.13 (20.04)	56.59 (24.21)	P=0.38	P=0.44	P=0.75
<i>CuPiD System usability [1-5]</i>									
I can turn on the smartphone easily			4.5 (0.9)						
I can turn on the CuPiD applications easily			4.6 (0.7)						
I think CuPiD is simple to use			4.3 (0.8)						
I can attach/remove the sensors easily			4.0 (1.3)						
I think I can use the system independently			4.0 (1.2)						

m: meters; s: seconds; DS: Double Support; GCT: gait cycle time; Phys: Physical; Ment: Mental

¹ analysis performed only on PD persons reporting freezing of gait; ^a significantly different from pretest; ^b significantly different from posttest

Values are presented as mean (\pm standard deviation)


Table 2 Adherence data

	CuPiD *	Control **	p- value
<i>Overall</i>			
PD persons [#]	20	18	
Total duration [minutes]	649.5 (234.7)	923.8 (342.6)	<0.01
Sessions [#]	28.3 (8.7)	27.9 (10.3)	0.91
<i>ABF-app/Gait advice</i>			
PD persons [#]	20	18	
Total duration [minutes]	494.7 (274.5)	742.7 (286.7)	0.01
Sessions [#]	20.7 (6.5)	20.7 (6.1)	0.99
<i>FOG-cue/FOG advice</i>			
PD persons [#]	10	7	
Total duration [minutes]	309.6 (141.5)	465.6 (179.1)	0.06
Sessions [#]	16.3 (4.5)	18.6 (1.5)	0.17

* Based on CuPiD-system adherence data

** Based on diary adherence data

Values are presented as mean (\pm standard deviation)



* Participated in Post- and Follow-up assessments for intention-to-treat analysis

Figure 1 Study flowchart

Electronic Supplementary material




Figure 2A illustrates the CuPiD system with the foot-mounted IMUs and the single large touchscreen button on the smartphone; 2B shows a schematic overview of the ABF-gait app with at the top a recording of a clinical optimal reference walk, which was captured under the therapist's supervision. The median value is then used as the reference value (full horizontal line). The pre-set therapeutic window (dotted horizontal lines) are the percentages above and below the reference value as determined by the therapist.


Table S1 Descriptive characteristics of training groups

	CuPiD (n=20)	Control (n=18)	p- value
<i>Demographics</i>			
Age [yrs]	67.30 (8.13)	66.11 (8.07)	0.65
Gender [m/f]	17/3	13/5	/
Persons with FOG [#]	14	10	0.50
Smartphone users [#]	6	5	1.00
<i>Disease severity</i>			
Disease duration [yrs]	10.65 (5.39)	11.67 (7.63)	0.64
MDS UPDRS III [0-132]	28.35 (14.77)	33.77 (14.36)	0.27
H&Y (2/2.5/3)	12/3/5	13/2/3	/
<i>Cognition</i>			
MoCA [0-0-30]	26.95 (2.19)	26.72 (2.11)	0.75


Yrs: years; m: male; f: female

Values are presented as mean (\pm standard deviation)


A Example 1 overview of Feedback and Adherence in 6 weeks




B Example 1 detailed gait performance in Week 4 Session 3



C Example 2 overview of Feedback and Adherence in 6 weeks



D Example 2 detailed gait performance in Week 5 Session 2



Examples of training performance and feedback in two participants using the CuPiD ABF function.

Panels A and C show (i) number of positive and corrective feedback events (y-axis) for a participant across sessions during the 6 training weeks (x-axis) and (ii) number of steps taken (y-axis) during the training sessions (x-axis).

Panels B and D, show details of feedback provided during the fourth-last session with on the x-axis the gait cycles per 30 minutes and on the y-axis % difference from the reference value of the training parameter that was targeted. Red dotted lines indicate the therapeutic window. The red dots indicate when corrective feedback was provided. The green dots indicate moments of positive feedback.

Example 1. Panel B shows that this participant trained stride length as the primary parameter and gait speed as the secondary parameter. Initial gait speed was too fast, which the participant corrected by adjusting stride length. This resulted in corrective feedback to 'take larger steps'. By the end of the session, the participant was able to keep both stride length and gait speed within the therapeutic window. If both the primary and secondary training parameters were outside the therapeutic window, only feedback was provided for the primary outcome, so as not to confuse the participant (example indicated by the black arrow in panel B).

Example 2. Panel D shows stride length to be the sole training parameter for this participant. By the end of the 30 minutes, it became difficult to maintain stride length, resulting in corrective feedback to 'take larger steps'. From the black arrow onwards, the system automatically increased the therapeutic window as not to overburden the participant with corrective feedback.